Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio.
| Revenue (Most Recent Fiscal Year) | $2.53B |
| Net Income (Most Recent Fiscal Year) | $451.12M |
| PE Ratio (Current Year Earnings Estimate) | 38.00 |
| PE Ratio (Trailing 12 Months) | 37.10 |
| PEG Ratio (Long Term Growth Estimate) | 2.97 |
| Price to Sales Ratio (Trailing 12 Months) | 6.58 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 31.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 39.33 |
| Pre-Tax Margin (Trailing 12 Months) | 22.09% |
| Net Margin (Trailing 12 Months) | 18.24% |
| Return on Equity (Trailing 12 Months) | 99.76% |
| Return on Assets (Trailing 12 Months) | 24.47% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.73 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $20.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $4.84 |
| Earnings per Share (Most Recent Fiscal Year) | $15.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $18.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 27.91M |
| Free Float | 22.19M |
| Market Capitalization | $18.68B |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 1.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |